<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-084X</journal-id>
<journal-title><![CDATA[Nucleus]]></journal-title>
<abbrev-journal-title><![CDATA[Nucleus]]></abbrev-journal-title>
<issn>0864-084X</issn>
<publisher>
<publisher-name><![CDATA[CUBAENERGIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-084X2019000200032</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Centro de Isótopos: acciones en beneficio de la salud pública]]></article-title>
<article-title xml:lang="en"><![CDATA[Center of Isotope: actions for the benefit of public health]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Arencibia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leyva Montaña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perera Pintado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández González]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morín Zorrilla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Isótopos (CENTIS)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<numero>66</numero>
<fpage>32</fpage>
<lpage>38</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-084X2019000200032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-084X2019000200032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-084X2019000200032&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN En tributo a los cinco siglos de ciudad el Centro de Isótopos hace recuento de su actividad. La obtención de compuestos marcados con radionucleidos y otros trabajos radioquímicos en el Instituto de Física Nuclear, inaugurado en 1969, estimularon las aplicaciones de las fuentes radiactivas abiertas, por lo que puede considerarse el antecedente organizado más palpable del centro. Posteriormente en los años 80, la Secretaria Ejecutiva para Asuntos Nucleares aceleró, diversificó y amplió las aplicaciones, desarrolló la formación de cuadros y especialistas y la colaboración internacional. La puesta en operación del Centro de Estudios Aplicados al Desarrollo de la Energía Nuclear coincidió con la consolidación de un grupo de instituciones de investigación y producción biotecnológica y con el auge de las aplicaciones en Medicina Nuclear. Pronto se reconoció que no era posible continuar el manejo de un inventario cada vez mayor de radionucleidos, por lo que se diseñó y construyó un centro especializado a ciclo completo: investigación-desarrollo, producción y comercialización, el CENTIS. Durante su integración en 1994 a la Agencia de Energía Nuclear, se concluyó la inversión y se establecieron las metodologías de producción de los más importantes radiofármacos. En más de 20 años de labor CENTIS se ha convertido en el principal soporte de la Medicina Nuclear del país. Con sus capacidades metrológicas en la magnitud radiactividad y sus investigaciones no clínicas y clínicas, se inserta de forma cada vez más estrecha en la vida socio-económica del país y su capital. En el trabajo se detallan los principales resultados de cada etapa en lo relacionado a la misión del centro y se hace una valoración técnica de hacia dónde se encaminan acciones en favor de sus sectores destino: salud e investigación biomédica. Lustros en favor de siglos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT To commemorate the 500th anniversary of the city of Havana, the Isotope Center reviews its activity since its creation. The production of radionuclidemarked compounds and other radiochemical work at the Institute of Nuclear Physics, inaugurated in 1969, stimulated the applications of open radioactive sources, which can be considered as the most tangible organized antecedent of the center. Later in the 1980s, the Executive Secretary for Nuclear Affairs accelerated, diversified and expanded nuclear applications, developed the training of highly qualified staff and experts as well as international cooperation. The creation of the Center for Applied Nuclear Development Studies coincided with the consolidation of a group of biotechnological research and production institutions and with these applications gaining importance in Nuclear Medicine. It was soon recognized that it was not possible to continue managing a growing inventory of radionuclides. As a result, CENTIS, a specialized center with a complete cycle, was designed and built, which comprised not only research and development, but also production and marketing. When in 1994 CENTIS became part of the Nuclear Energy Agency, investment was concluded and the production methodologies of the most important radiopharmaceuticals were established. In more than 20 years of work CENTIS has become the main support of Nuclear Medicine in the country. With its metrological capabilities in the magnitude of radioactivity and its non-clinical and clinical research, it is increasingly part of the socio-economic life of the country and its capital. In this paper the main results of each stage are detailed in relation to the mission of the center and a technical assessment is made regarding the actions taken to favor their target sectors: health and biomedical research. Periods of five years in favor of centuries.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cuba]]></kwd>
<kwd lng="es"><![CDATA[compuestos marcados]]></kwd>
<kwd lng="es"><![CDATA[aplicaciones de los isótopos]]></kwd>
<kwd lng="es"><![CDATA[usos]]></kwd>
<kwd lng="es"><![CDATA[medicina nuclear]]></kwd>
<kwd lng="es"><![CDATA[instalaciones nucleares]]></kwd>
<kwd lng="es"><![CDATA[producción de isótopos]]></kwd>
<kwd lng="en"><![CDATA[Cuba]]></kwd>
<kwd lng="en"><![CDATA[labelled compounds]]></kwd>
<kwd lng="en"><![CDATA[isotope applications]]></kwd>
<kwd lng="en"><![CDATA[uses]]></kwd>
<kwd lng="en"><![CDATA[nuclear medicine]]></kwd>
<kwd lng="en"><![CDATA[nuclear facilities]]></kwd>
<kwd lng="en"><![CDATA[production]]></kwd>
<kwd lng="en"><![CDATA[isotope production]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="book">
<source><![CDATA[Centro de Producción y Desarrollo de Compuestos Marcados y Radiofármacos. Tarea de proyección]]></source>
<year>1988</year>
<publisher-name><![CDATA[SEAN, UPCIN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[OLIVÉ ÁLVAREZ]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avances y proyecciones de la radioquímica y de las técnicas analíticas nucleares]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>1989</year>
<numero>7</numero>
<issue>7</issue>
<page-range>31-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[OLIVÉ ÁLVAREZ]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[ISAAC TEJERA]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control físico-químico de calidad del 131I-2-yodohipurato sódico]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>1992</year>
<numero>12</numero>
<issue>12</issue>
<page-range>19-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ABDALA JIMÉNEZ]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[HERNÁNDEZ GONZÁLEZ]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[OLIVÉ ÁLVAREZ]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevo kit para la preparación de 99mTc-MAG3&#8221;]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>1993</year>
<numero>15</numero>
<issue>15</issue>
<page-range>23-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[LÓPEZ RODRÍGUEZ]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[HERNÁNDEZ GONZÁLEZ]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Método rápido para la determinación de pureza radioquímica del tecnecio 99m-Tc MIBI]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>1995</year>
<numero>18</numero>
<issue>18</issue>
<page-range>17-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="">
<source><![CDATA[Examen de la tecnología nuclear 2006. Informe del Director General]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="book">
<collab>International Atomic Energy Agency (IAEA)</collab>
<source><![CDATA[Technetium-99 radiopharmaceuticals: manufacture of Kits. Technical Reports]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Vienna ]]></publisher-loc>
<publisher-name><![CDATA[IAEA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofármacos de Galio- 68]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2012</year>
<numero>51</numero>
<issue>51</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PÉREZ PIJUÁN]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Centro de Isótopos: continuidad, presencia y proyecciones en su Aniversario 15]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2012</year>
<numero>52</numero>
<issue>52</issue>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LEYVA]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MORÍN]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofármacos en inmunocentelleografía y Radioinmunoterapia&#8221;]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2012</year>
<numero>52</numero>
<issue>52</issue>
<page-range>68-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ALBERTI RAMÍREZ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[CRUZ MORALES]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Itrio-90 como radionúclido para terapia]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2012</year>
<numero>52</numero>
<issue>52</issue>
<page-range>62-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HERNÁNDEZ]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigaciones no clínicas en el Centro de Isótopos en función de la industria farmacéutica y biotecnológica&#8221;]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2012</year>
<numero>52</numero>
<issue>52</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="book">
<source><![CDATA[Expediente del Resultado Fosfato de Fosfato de Cromo (III)-32P de CENTIS en el tratamiento de la sinovitis crónica]]></source>
<year>2013</year>
<publisher-name><![CDATA[AENTA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La producción de radiofármacos en CENTIS]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2014</year>
<numero>56</numero>
<issue>56</issue>
<page-range>27-32</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy and Radioimmunotherapy in Cuba: Experiences with Labeled Monoclonal Antibodies for Cancer Diagnosis and Treatment (1993-2013)]]></article-title>
<source><![CDATA[MEDICC Review]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>55-60</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[HERNANDEZ]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[COCA]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lymphoscintigraphy for the assessment of autologous stem cell implantation for chronic lymphedema]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2015</year>
<volume>40</volume>
<page-range>217-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[CROMBET]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[PRATS]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy with 99mTc-Nimotuzumab for planning immunotherapy in patients with bone metastases due to prostate cancer]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2016</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>244-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[TAYLOR DELGADO]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posibilidades del mercado de radiofármacos. Escenario cubano]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2017</year>
<numero>62</numero>
<issue>62</issue>
<page-range>25-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[ROJO MARTÍNEZ]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[FIRVIDA LAMELAS]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio de factibilidad &#8220;Recapitalización tecnológica de CENTIS&#8221;]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEÑA]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[CROMBET]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[BATISTA]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[VERGARA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[PERERA]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoscintigraphy with 99mTc-Nimotuzumab in Patients with Non-Small Cell Lung Cancer that will Receive Therapy with the Monoclonal Antibody]]></article-title>
<source><![CDATA[Ann Clin Case Rep]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>1354</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="">
<source><![CDATA[Centro de Isótopos (CENTIS). Balance anual de trabajo]]></source>
<year>2018</year>
<publisher-loc><![CDATA[CENTIS ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
